SCHEMBL6701480

SCHEMBL6701480

C#CCOCCn1cnc2c(N(C(=O)OCc3ccccc3)C(=O)OCc3ccccc3)nc3ccccc3c21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.34
POLB P06746 3/20 0.34
TLR7 Q9NYK1 2/20 0.34
HRH2 P25021 1/20 0.34
ADRA1D P25100 1/20 0.34
HTR2A P28223 1/20 0.34
ADORA2A P29274 1/20 0.34
ADRA1A P35348 1/20 0.34
NUDT1 P36639 1/20 0.34
HTR2B P41595 1/20 0.34
PDE4D Q08499 1/20 0.34
KCNH2 Q12809 1/20 0.34
TSHR P16473 2/20 0.32
RAB9A P51151 2/20 0.32
MAPK1 P28482 1/20 0.32
ALDH1A1 P00352 3/20 0.32
HTT P42858 3/20 0.32
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
GAA P10253 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6108124 0.77 DGAT1 (0.34) LMNATLR7RAB9AALDH1A1HTT
SCHEMBL6104144 0.76 TLR7 (0.56) LMNAPOLBTLR7HRH2ADRA1D
SCHEMBL6701764 0.76 LMNA (0.40) LMNAPOLBTLR7HRH2ADRA1D
SCHEMBL6700062 0.73 LMNA (0.38) LMNAPOLBTLR7HRH2ADRA1D
SCHEMBL6108450 0.73 ALDH1A1 (0.40) LMNAPOLBTLR7HRH2ADRA1D
SCHEMBL6105466 0.72 TLR7 (0.35) LMNAPOLBTLR7HRH2ADRA1D
SCHEMBL6106063 0.71 TLR7 (0.42) LMNAPOLBTLR7HRH2ADRA1D
SCHEMBL6104983 0.71 TLR7 (0.42) LMNAPOLBTLR7HRH2ADRA1D
SCHEMBL6702016 0.69 LMNA (0.41) LMNAPOLBTLR7HRH2ADRA1D
SCHEMBL6107128 0.69 SMN1; SMN2 (0.45) LMNAPOLBRAB9AMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-04-15 US disclosed
US-6664260-B2 Viricides; anticarcinogneic agents; induction cytokine biosynthesis 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US disclosed
EP-1339715-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-03 EP disclosed
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
WO-2002046193-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 LMNA 3958/4885POLB 3364/4885TLR7 35/4885
US-20040072858-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 LMNA 3958/4885POLB 3364/4885TLR7 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.